Fig. 5.

OTUD1 attenuates the synergistic effect of Sorafenib and BH3 mimetic compound in cancer cells. a Huh7 cells were stimulated with or without Sorafenib (10 µM) for 6 h. The cells were then harvested and subjected to SDS-PAGE and analysed by immunoblotting with the indicated antibodies. b Huh7 stable cell lines expressing empty vector or OTUD1 were treated with or without Sorafenib (10 µM) for 3 h. The cells were then harvested and subjected to SDS-PAGE and analysed by immunoblotting with the indicated antibodies. c Huh7 stable cell lines expressing empty vector or OTUD1 were treated with Sorafenib (2 µM) plus ABT-263 (5 µM) and the cell viabilities were determined. **p < 0.01